Lilly’s Tirzepatide For Obesity Faces Uphill Road To Medicare Part D Acceptance

Eli Lilly’s drug could join Novo Nordisk’s Wegovy on the market in the next year or so as treatments offering significantly more weight loss than previous drugs have been able to. Could that open the door to greater access?